Loading…
science
Hosted by Chris O'Brien · science · EN · 35 episodes
Welcome to Few & Far Between! Melissa Alesse, President of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
31%
Guest openness
Selective
Sign up to generate a grounded pitch for Few & Far Between: How Biotech Gets Built.
Signup to Generate a PitchFew & Far Between: How Biotech Gets Built is a science podcast hosted by Chris O'Brien, with 35 episodes on record and a Required Pod Score of 81.
Chris O'Brien hosts Few & Far Between: How Biotech Gets Built, a science show with 35 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Episode #74
Today on the Biorasi Few & Far Between Podcast: Host Melissa Alesse welcomes Jason Tardio, President and COO of Immunic Therapeutics, to the podcast to explore the biotech journey to R&D and commercialization. We'll also look into Immunic's novel treatments for multiple sclerosis, true team accountability, what makes biotech and big pharma so different. Watch this episode today!
Few & Far Between: How Biotech Gets Built
Today on the Biorasi Few & Far Between podcast: Host Melissa Alesse welcomes Isaac Stoner, CEO of MindImmune Therapeutics, back to the podcast for a conversation on the evolving science of Alzheimer's disease and the challenges of biotech leadership. We'll explore Alzheimer's through the lens of the immune system, discuss drug development from the perspective of investors and operators, and dive into the power of networking in Boston's biotech ecosystem. And be sure to stick around for our lightning round - quick answers to important questions. Watch this episode today!
Episode #72
Today on the Biorasi Few & Far Between podcast: What's trending in the CRO market? Find out as host Melissa Alesse welcomes Joel White, owner of Marketcap Consulting and 20+ year veteran of the CRO industry. We'll uncover the latest in CRO strategy, biotech funding, and clinical trial program pricing. And be sure to stick around for our lightning round - quick answers to important questions. Watch this episode today!
Episode #71
<p>Today on the Biorasi Few & Far Between podcast: <br /><br />Join new host Melissa Alesse and former host Chris O'Brien - CEO at Rancho BioSciences and Biorasi Board member - as they explore the origins and evolution of our podcast and what we've learned along the way.<br /><br />We dive deep into the importance of long-form media and thought leadership, AI's continuous evolution, and CROs from the CEO's POV.<br /><br />Watch this episode today!</p>
Episode #69
<p>Today on the Biorasi podcast, we look back on three years of AI innovation in healthcare and clinical trials - breaking new boundaries and a creating a new reality across all industries.</p> <p>Host Chris O'Brien welcomes back Zak Kohane, AI Oracle and Professor and Chair of Biomedical Informatics at Harvard Medical School. We'll journey back to Zak's first appearance on the podcast and take stock of what three years means to AI development including widespread adoption by patients and physicians, how cancer still outsmarts today's LLMs, and the importance of sharing prompts with fellow AI travellers.</p> <...
Recent guests on Few & Far Between: How Biotech Gets Built. Study who booked and why before you pitch.
Sponsor detection runs nightly. Check back soon.
Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
FAQs
If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.
Founder Solo gives you 50 AI pitches per month using the credit model (Standard pitches cost 1 credit, Enriched pitches cost 2). Founder Pro raises that to 200 credits per month and adds full Booking Probability access, unlimited Magic Match, Apollo enrichment credits, and data export capabilities. Both plans use the same credit system, so you can stretch your monthly budget further by using Standard-mode drafting.
Agency tiers have no base fee. You pay per managed client and per talent profile. Agency Standard is $199 per client per month; Agency Pro is $399 per client per month. Both add $39 per talent profile per month. Your own team's user seats are always free.
A talent profile represents one person (founder, executive, or spokesperson) you are booking onto podcasts. It includes their bio, topics, headshots, and outreach history. Team plans include 5 profiles; agency plans are pay-as-you-go.
Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.
Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.
You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.
Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.
That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.
